Luping Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luping Pan has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Jinju Guo
Department of Oncology, The Shangrao Medical Center, Second Affiliated Hospital of Nanchang University, Shangrao, Jiangxi, China
1 shared publicationWei Liu
The Medical College of Nanchang University, Nanchang, Jiangxi, China
1 shared publication- Xia Wang
The Second Affiliated Hospital of Nanchang University
1 shared publication Yuan Xiang
Nanwai Community Health Service Center, Zhanggong District, Ganzhou, Jiangxi, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2025 (1) , 9983293
Divergent Survival Outcomes With Adjuvant Chemotherapy in Stage IA Ovarian Clear Cell Carcinoma: Insights From the SEER Database
Background: This study aims to evaluate the impact of adjuvant chemotherapy on cancer‐specific survival (CSS) and overall survival (OS) in patients with Stage IA ovarian clear cell carcinoma (OCCC) using data from the Surveillance, Epidemiology, and End Results (SEER) database. Methods: We conducted a retrospective cohort study utilizing SEER data (2000–2021) to compare the prognosis of Stage IA OCCC patients who received adjuvant chemotherapy versus those who did not. Propensity score matching (PSM) was used to balance baseline characteristics between the groups. Competing risks regression and multivariate Cox regression analyses identified prognostic factors for CSS and OS. Results: A total of 1422 Stage IA OCCC patients were identified. After PSM, 776 patients (388 in each group) were included. For patients aged ≤ 50 years, chemotherapy was linked to worse CSS (89.5% vs. 96.2%, p = 0.007) and OS (89.3% vs. 95.9%, p = 0.008). Conversely, in patients aged > 70 years, chemotherapy was associated with improved CSS (93.0% vs. 81.9%, p = 0.038) and OS (86.0% vs. 72.4%, p = 0.006). These trends remained after PSM. Multivariate analysis showed that chemotherapy had little impact on OS and CSS. Subgroup analysis further indicated that chemotherapy negatively affected CSS and OS in patients aged ≤ 50 years. Conclusions: Adjuvant chemotherapy did not significantly improve survival outcomes in patients with Stage IA OCCC. However, its effects were age‐dependent, with older patients (> 70 years) experiencing improved survival, while younger patients (≤ 50 years) exhibited worse outcomes. These findings underscore the importance of individualized treatment strategies for Stage IA OCCC.
- 1 January 2025
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2025 (1) , 9983293
Open AccessDivergent Survival Outcomes With Adjuvant Chemotherapy in Stage IA Ovarian Clear Cell Carcinoma: Insights From the SEER Database
Background: This study aims to evaluate the impact of adjuvant chemotherapy on cancer‐specific survival (CSS) and overall survival (OS) in patients with Stage IA ovarian clear cell carcinoma (OCCC) using data from the Surveillance, Epidemiology, and End Results (SEER) database. Methods: We conducted a retrospective cohort study utilizing SEER data (2000–2021) to compare the prognosis of Stage IA OCCC patients who received adjuvant chemotherapy versus those who did not. Propensity score matching (PSM) was used to balance baseline characteristics between the groups. Competing risks regression and multivariate Cox regression analyses identified prognostic factors for CSS and OS. Results: A total of 1422 Stage IA OCCC patients were identified. After PSM, 776 patients (388 in each group) were included. For patients aged ≤ 50 years, chemotherapy was linked to worse CSS (89.5% vs. 96.2%, p = 0.007) and OS (89.3% vs. 95.9%, p = 0.008). Conversely, in patients aged > 70 years, chemotherapy was associated with improved CSS (93.0% vs. 81.9%, p = 0.038) and OS (86.0% vs. 72.4%, p = 0.006). These trends remained after PSM. Multivariate analysis showed that chemotherapy had little impact on OS and CSS. Subgroup analysis further indicated that chemotherapy negatively affected CSS and OS in patients aged ≤ 50 years. Conclusions: Adjuvant chemotherapy did not significantly improve survival outcomes in patients with Stage IA OCCC. However, its effects were age‐dependent, with older patients (> 70 years) experiencing improved survival, while younger patients (≤ 50 years) exhibited worse outcomes. These findings underscore the importance of individualized treatment strategies for Stage IA OCCC.